That is what we want; in line with previous. We don't want anything different for this Ph-I of INSIGHT-004, all we needed to know was FINAK results welcoming us to phase II. Note the small number of patients as per Ph I setting. These is not much validity in further analysis as pretty much a Yay/Nay answer was required to answer THE one question of safety in a ph-I trial, hence low numbers of patients.
Ann: Immutep Reports Positive Final Data from INSIGHT-004 trial, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.5¢ | $251.5K | 806.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 121215 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 2864 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |